Novel application of n-butanol-2-O-(L-pyroglutamate-N-6-)-alpha-D-fructofuranoside
The present invention discloses novel application of n-butanol-2-O-(L-pyroglutamate-N-6-)-alpha-D-fructofuranoside, including application in Alzheimer's disease (AD), application in neuronal cell proliferation, application in improvement of learning and memory and cognitive ability and application in inhibiting the activity of AchE, increasing the content of ChAT and Ach. L-pyroglutamate alpha inthe present invention can bind to a muscarinic receptor M3 due to the spatial configuration of the L-pyroglutamate alpha, after the L-pyroglutamate alpha binds to the muscarinic receptor M3, the Ach in the brain of an AD patient is retained, so that the content of Ach is increased, while L-pyroglutamate beta cannot bind to the muscarinic receptor M3, which also shows that L-pyroglutamate alpha hasexcellent AD resisting function. The present invention provides an effective basis for L-pyroglutamate alpha in resisting AD through molecular biology, thereby providing new ideas for the developmentof anti-AD drugs..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 22. Sept. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEI XIA [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-09-22, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111686122 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006569102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006569102 | ||
| 003 | DE-627 | ||
| 005 | 20230504063713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA006569102 | ||
| 035 | |a (EPA)CN111686122 | ||
| 035 | |a (EPA)72487095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEI XIA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel application of n-butanol-2-O-(L-pyroglutamate-N-6-)-alpha-D-fructofuranoside |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-09-22, Last update posted on www.tib.eu: 2022-04-10, Last updated: 2023-02-09 | ||
| 520 | |a The present invention discloses novel application of n-butanol-2-O-(L-pyroglutamate-N-6-)-alpha-D-fructofuranoside, including application in Alzheimer's disease (AD), application in neuronal cell proliferation, application in improvement of learning and memory and cognitive ability and application in inhibiting the activity of AchE, increasing the content of ChAT and Ach. L-pyroglutamate alpha inthe present invention can bind to a muscarinic receptor M3 due to the spatial configuration of the L-pyroglutamate alpha, after the L-pyroglutamate alpha binds to the muscarinic receptor M3, the Ach in the brain of an AD patient is retained, so that the content of Ach is increased, while L-pyroglutamate beta cannot bind to the muscarinic receptor M3, which also shows that L-pyroglutamate alpha hasexcellent AD resisting function. The present invention provides an effective basis for L-pyroglutamate alpha in resisting AD through molecular biology, thereby providing new ideas for the developmentof anti-AD drugs. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI BING |4 aut | |
| 700 | 0 | |a LEI SHUANGYUAN |4 aut | |
| 700 | 0 | |a ZHANG ZHENGYI |4 aut | |
| 700 | 0 | |a ZHANG ZIHAN |4 aut | |
| 700 | 0 | |a WANG LAI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 22. Sept. |
| 773 | 1 | 8 | |g year:2020 |g day:22 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72487095/publication/CN111686122A1?q=CN111686122 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 22 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 22 |c 09 | ||